<DOC>
	<DOCNO>NCT00004815</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess safety efficacy recombinant human insulin-like growth factor 1 patient Werner 's syndrome osteoporosis .</brief_summary>
	<brief_title>Descriptive Study Recombinant Human Insulin-Like Growth Factor Osteoporosis Werner 's Syndrome</brief_title>
	<detailed_description>PROTOCOL OUTLINE : The patient receive subcutaneous recombinant human insulin-like growth factor 1 daily 7 month . The dose adjust accord serum hormone level biological marker bone turnover . Concurrent therapy include metabolic diet , calcium citrate , estradiol .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Werner Syndrome</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Werner 's syndrome osteoporosis low serum insulinlike growth factor 1 level Patient treat protocol 049215300 `` Metabolic Skeletal Effects Exogenous Recombinant Human InsulinLike Growth Factor ''</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>Werner 's syndrome</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>rare disease</keyword>
</DOC>